Healthcare

FDA approves first COVID-19 drug to treat children under 12 

1 Mins read

On Monday, April 25, the U.S. Food and Drug Administration (FDA) made a highly anticipated announcement. According to the FDA’s official news release, it has approved the use of Veklury (remdesivir) to treat COVID-19 for children under the age of 12.

To receive this drug, a child must weigh at least 6.6 pounds (3 kilograms) and test positive for COVID. This includes both those hospitalized and not who have mild to moderate symptoms and are at an increased risk for a severe case of the virus, which could be fatal.

Veklury is now the first FDA-approved COVID-19 treatment for pediatric patients under the age of 12. The omicron variant has caused cases to spike in children. So, this announcement has revoked the former ‘emergency use only’ authorization to use Veklury to treat the youngest COVID patients. Monoclonal antibody therapy still has emergency use authorization from the FDA, but it is administered on a risk-benefit analysis.

Patrizia Cavazzoni, M.D., the director of the FDA’s Center for Drug Evaluation and Research, lauded the decision. She pointed out a continued need for “safe and effective COVID-19 treatment options for this population” due to the virus causing severe illness in children. Though omicron has proven to be less severe than other COVID-19 variants, it has resulted in a fourfold increase in pediatric hospitalizations.

Veklury is not a substitute for vaccination, but juveniles have limited vaccine options at this time. It has been shown to reduce the chances of hospitalization and death for patients of multiple ages, and the same efficacy is seen in children. Approved for hospitalized COVID patients in October of 2020, remdesivir is one of the first drugs to be cleared for treating the virus.

Side effects include increased liver enzymes, changes in heart rate and/or blood pressure, fever, wheezing, facial swelling, nausea, sweating, shivering, and low blood oxygen levels. However, these side effects tend to be relatively mild. Veklury is administered as an injection, and its efficacy has been demonstrated in clinical trials among adults.

The FDA continues to encourage those eligible to receive the COVID-19 vaccine and booster shots.

Related posts
BusinessFeaturedHealthcare

Give Your Family The Good Taste Of Health With Healthy Crunch!

1 Mins read
We all know that healthy eating is essential, but it can be hard to find snacks that are good for you, and…
Healthcare

FDA panel votes unanimously in favor of COVID shots for youngest children

2 Mins read
Although COVID vaccines and boosters have been made widely available, a large demographic has not been eligible for this critical protection from…
Healthcare

Safe for Dogs, Neutralises Delta & Omicron Variants: What is Anocovax, India's First Covid Jab for Animals

1 Mins read
While there have been several debates over the passing of the virus to animals, several studies have shown that Covid-19 can spread…

Leave a Reply

Your email address will not be published.